Kunzea oil for the management of mild to moderate psoriasis (a common, chronic, relapsing, immune-mediated skin disease: a pilot randomised controlled trial.

Phase 2

Completed

• Conditions: Psoriasis of the body and scalp; Skin - Dermatological conditions; Alternative and Complementary Medicine - Other alternative and complementary medicine; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12614001014640
• Lead Sponsor: niversity of Tasmania

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09-22
• Last Update Posted: 2020-01-13

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Entry criteria required a clinical diagnosis of psoriasis involving greater than or equal to 10% of the body surface.

Exclusion Criteria

The main exclusion criteria were current diagnosis of unstable psoriasis, atopic dermatitis and other skin conditions (e.g. seborrhoeic dermatitis, contact dermatitis, cutaneous mycosis, presence of pigmentation, extensive scarring, pigmented lesion) confounding psoriasis assessment, pregnancy, breast-feeding, and use of medications that are known to exacerbate the course of psoriasis (lithium, beta adrenergic blocking agents, antimalarial drugs).
Subjects with flexural and pustular psoriasis were not considered because of their rarity and potential treatment difficulties with the trial medications. All patients had a 6-week washout period for systemic therapy (including phototherapy) and 2 weeks for topical psoriatic treatment before receiving the study drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified